Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
IDEXX LABORATORIES INC /DE
Last earnings -0.0% on 2026-05-05
Revenue grew 10.4% YoY.
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
IDEXX LABORATORIES INC /DE shows $4.30B in FY2025 revenue (+10.4% YoY), a 24.6% net margin, and 66.0% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0000874716, latest 10-Q filed 2026-05-05) · EODHD · rules-based read · as of 6/17/2026, 7:47:01 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $3.22B | $3.37B | $3.66B | $3.90B | $4.30B |
| Gross profit | $1.89B | $2.00B | $2.19B | $2.38B | $2.66B |
| Operating income | $932M | $899M | $1.10B | $1.13B | $1.36B |
| Net income | $745M | $679M | $845M | $888M | $1.06B |
| Diluted EPS | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 |
| Net margin | 23.2% | 20.2% | 23.1% | 22.8% | 24.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
58 tracked peers · median
| 2026-06-01 | FENNELL GEORGE Executive Vice President | Exercise | 639.00 | |
| 2026-06-01 | FENNELL GEORGE Executive Vice President | Tax | 284.00 @ $566.79 | $161K |